Resin acids and Rosin acids, fumarated, esters with pentaerythritol

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

weight of evidence

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guideline and the study was conducted under GLP conditions.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2010

Report date:

2010

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

Resin acids and rosin acids, fumerated, esters with pentaerythritol

IUPAC Name:

Resin acids and rosin acids, fumerated, esters with pentaerythritol

Constituent 2

Reference substance name:

Resin acids and Rosin acids, fumarated, esters with pentaerythritol

EC Number:

305-514-1

EC Name:

Resin acids and Rosin acids, fumarated, esters with pentaerythritol

Cas Number:

94581-15-4

Molecular formula:

Unspecified

IUPAC Name:

Resin acids and Rosin acids, fumarated, esters with pentaerythritol

Details on test material:

Sponsor's identification :CAS No 94581-15-4 Resin acids and rosin acids, fumerated, esters with pentaerythritol
Supplier : Arizona Chemicals
Description : amber coloured solid
Batch number : 23248
Date received : 13 August 2009
Expiry date : 13 August 2010
Storage conditions: approximately -20°C in the dark

In vivo test system

Test animals

Species:

mouse

Strain:

other: CBA/Ca (CBA/CaOlaHsd)

Sex:

female

Details on test animals and environmental conditions:

Female CBAlCa (CBAlCaOlaHsd) strain mice were supplied by Harlan Laboratories UK Limited, Bicester, Oxon, UK. On receipt the animals were randomly allocated to cages.

The animals were nulliparous and non-pregnant. After an acclimatisation period of at least five days the animals were selected at random and given a number unique within the study by indelible ink-marking on the tail and a number written on a cage card.

At the start of the study the animals were in the weight range of 15 to 23 g, and were eight to twelve weeks old.

The animals were individually housed in suspended solid-floor polypropylene cages furnished with softwood woodflakes. Free access to mains tap water and food (2014 Teklad Global Rodent diet supplied by Harlan Teklad, Blackthorn, Bicester, Oxon, UK) was allowed throughout the study.

The temperature and relative humidity were controlled to remain within target ranges of 19 to 25°C and 30 to 70%, respectively. Any occasional deviations from these target swere considered not to have affected the purpose or integrity of the study. The rate of air exchange was approximately fifteen changes per hour and the lighting was controlled by a time switch to give twelve hours continuous light (06.00 to 18.00) and twelve hours darkness.

The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study.

Study design: in vivo (LLNA)

Vehicle:

dimethylformamide

Remarks:

EXAMPLE: Please see below for Vehicle Determination Record

Concentration:

Each group was exposed to concentrations of 50%, 25% or 10% v/v (in dimethyl formamide)

No. of animals per dose:

Groups of four mice were treated

Details on study design:

RANGE FINDING TESTS:
Using available information regarding the systemic toxicity/irritancy potential of the test material, a preliminary screening test was performed using one mouse. The mouse was treated by daily application of 25 µl of the test material at a concentration of 50% w/w in dimethyl formamide, to the dorsal surface of each ear for three consecutive days (Days 1, 2, 3). The mouse was observed twice daily on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Any signs of toxicity or excessive local irritation noted during this period were recorded. The bodyweight was recorded on Day 1 (prior to dosing) and on Day 6.

- Lymph node proliferation response:
Clinical observations, bodyweight and mortality data are give in the results section (table 1).

No signs of systemic toxicity were noted. Fur loss was noted on Days 3 to 6.

Based on this information the dose levels selected for the main test were 50%, 25% and 10% v/v in dimethyl formamide.

MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT

- Name of test method:
Local Lymph Node Assay in the Mouse. The assay has undergone extensive inter-laboratory validation and has been shown to reliably detect test materials that are moderate to strong sensitisers.

- Criteria used to consider a positive response:
The proliferation response of lymph node cells was expressed as the number of radioactive disintegrations per minute per lymph node(dpm/node) and as the ratio of 3HTdR incorporation in lymph node cells of test nodes relative to that recorded for the control nodes (stimulation Index).

The test material will be regarded as a sensitiser if at least one concentration of the test material results in a threefold or greater increase in 3HTdR incorporation compared to control values. Any test material failing to produce a threefold or greater increase in 3HTdR incorporation will be classified as a "non-sensitier".

TREATMENT PREPARATION AND ADMINISTRATION:
For the purpose of the study, the test material was freshly prepared as a solution in dimethyl formamide. This vehicle was chosen as it produced the highest concentration that was suitable for dosing. The concentrations used are given above.

Determination, by analysis, of the concentration, homogeneity and stability of the test material preparations was not appropriate because it was not specified in the Study Plan and is not a requirement of the Test Guidelines.

The preliminary screening test suggested that the test material would not produce systemic toxicity or excessive local irritation at the highest suitable concentration. The mice were treated by daily application of 25 µl of the appropriate concentration of the test material to the dorsal surface of each ear for three consecutive days (Days 1, 2 and 3). The test material formulation was administered using an automatic micropipette and spread over the dorsal surface of the ear using the tip of the pipette.

3H-Methyl Thymidine Administration:
Five days following the first topical application of the test material (Day 6) all mice were injected via the tail vein with 250 µl of phosphate buffered saline (PBS) containing 3H-methyl thymidine (3HTdR: 80 µCi/ml, specific activity 2.0 Ci/mmol, GE Healthcare UK Ltd) giving a total of 20 µCi to each mouse.

Positive control substance(s):

hexyl cinnamic aldehyde (CAS No 101-86-0)

Statistics:

None provided.

Results and discussion

Positive control results:

A group of five animals was treated with 50 µl (25 µl per ear) of α Hexylcinnamaldehyde, tech., 85% as a solution in dimethyl formamide at a concentration of 15% v/v. A further control group of five animals was treated with dimethyl formamide alone.

The Stimulation Index expressed as the mean radioactive incorporation for the treatment group divided by the mean radioactive incorporation of the vehicle control group is as follows:
Concentration (% v/v) in
dimethyl formamide Stimulation Index Result
15 5.16 Positive

Conclusion. α-Hexylcinnamaldehyde, tech., 85% was considered to be a sensitiser under the conditions of the test.

In vivo (LLNA)

Results

Results 1

Key result

Parameter:

SI

Value:

1.8

Test group / Remarks:

10% Concentration (%w/w) in dimethyl formamide

Results 2

Key result

Parameter:

SI

Value:

2.52

Test group / Remarks:

25% Concentration (%w/w) in dimethyl formamide

Results 3

Key result

Parameter:

SI

Value:

4.24

Test group / Remarks:

50% Concentration (%w/w) in dimethyl formamide

Results 4

Key result

Parameter:

EC3

Value:

32

Test group / Remarks:

concentration of test material expected to cause a 3 fold increase in 3HTdR incorporation (EC3value) was calculated to be 32.0%

Any other information on results incl. tables

Table1              Clinical Observations, Bodyweight and Mortality Data – Preliminary Screening Test

Concentration (%w/w) in dimethyl formamide	Animal Number	Bodyweight (g)		Day
				1		2		3		4	5	6
		Day 1	Day 6	Pre-Dose	Post Dose	Pre-Dose	Post Dose	Pre-Dose	Post Dose
50	S-1	18	18	0	0	0	0	0Fl	0Fl	0Fl	0Fl	0Fl

0=      No signs of systemic toxicity

Fl =     Fur loss

Table2              Disintegrations per Minute, Disintegrations per Minute/Node and Stimulation Index

Concentration (%w/w) in dimethyl formamide	dpm	dpm/Node^a	Stimulation Index^b	Result
Vehicle	8806.49	1100.81	na	na
10	15852.72	1981.59	1.80	Negative
25	22200.63	2775.08	2.52	Negative
50	37350.24	4668.78	4.24	Positive

dpm=  Disintegrations per minute

a=      Disintegrations per minute/node obtained by dividing the disintegrations per minute value by 8 (total number of lymph nodes)

b=      Stimulation Index of 3.0 or greater indicates a positive result

na =    Not applicable

Table3              Individual Clinical Observations and Mortality Data

Concentration (% w/w) in dimethyl formamide	Animal Number	Day 1		Day 2		Day 3		Day 4	Day 5	Day 6
		Pre-Dose	Post Dose	Pre-Dose	Post Dose	Pre-Dose	Post Dose
Vehicle	1-1	0	0	0	0	0	0	0	0	0
	1-2	0	0	0	0	0	0	0	0	0
	1-3	0	0	0	0	0	0	0	0	0
	1-4	0	0	0	0	0	0	0	0	0
10	2-1	0	0	0	0	0	0	0	0	0
	2-2	0	0	0	0	0	0	0	0	0
	2-3	0	0	0	0	0	0	0	0	0
	2-4	0	0	0	0	0	0	0	0	0
25	3-1	0	0	0	0	0	0	0	0	0
	3-2	0	0	0	0	0	0	0	0	0
	3-3	0	0	0	0	0	0	0	0	0
	3-4	0	0	0	0	0	0	0	0	0
50	4-1	0	0	0	0Fl	0Fl	0Fl	0Fl	0Fl	0Fl
	4-2	0	0	0	0Fl	0Fl	0Fl	0Fl	0Fl	0Fl
	4-3	0	0	0	0Fl	0Fl	0Fl	0Fl	0Fl	0Fl
	4-4	0	0	0	0Fl	0Fl	0Fl	0Fl	0Fl	0Fl

0=      No signs of systemic toxicity

Fl =     Fur loss

Table4              Individual Bodyweights and Bodyweight Changes

Concentration (% w/w) in dimethyl formamide	Animal Number	Bodyweight (g)		Bodyweight Change (g)
		Day 1	Day 6
Vehicle	1-1	19	20	1
	1-2	20	21	1
	1-3	20	20	0
	1-4	17	18	1
10	2-1	18	18	0
	2-2	20	19	-1
	2-3	16	17	1
	2-4	19	19	0
25	3-1	20	20	0
	3-2	19	18	-1
	3-3	19	19	0
	3-4	18	19	1
50	4-1	16	17	1
	4-2	16	17	1
	4-3	18	18	0
	4-4	18	18	0

Applicant's summary and conclusion

Interpretation of results:

other: Sensitising

Remarks:

Criteria used for interpretation of results: EU

Conclusions:

Under the UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) guidelines, as well as the OECD 429 test guidelines a EC3 ≥ 3 value is required to consider a substance as positive when testing using the LLNA method. Results from this study indicated that the concentration of test material expected to cause a 3-fold increase in3HTdR incorporation (EC3value) was calculated to be 32.0%. Based on the results of this study, resin acids and rosin acids, fumerated, esters with pentaerythritol is classifiable for skin sensitization according to UN Globally Harmonized System of Classification or EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.

Executive summary:

A study was performed to assess the skin sensitisation potential of the test material in the CBA/Ca strain mouse following topical application to the dorsal surface of the ear. The method was designed to meet the requirements of the following:

§        OECD Guideline for the Testing of Chemicals No. 429 "Skin Sensitisation: Local Lymph Node Assay" (adopted 24 April 2002)

§        Method B42 Skin Sensitisation (Local Lymph Node Assay) of CommissionRegulation (EC) No. 440/2008

Following a preliminary screening test in which no clinical signs of toxicity were noted at a concentration of 50% w/w, this concentration was selected as the highest dose investigated in the main test of the Local Lymph Node Assay. Three groups, each of four animals, were treated with 50 µl (25 µl per ear) of the test material as a solution in dimethyl formamide at concentrations of 50%, 25% or 10% w/w. A further group of four animals was treated with dimethyl formamide alone.

The Stimulation Index expressed as the mean radioactive incorporation for each treatment group divided by the mean radioactive incorporation of the vehicle control group are as follows:

Concentration (%w/w) in dimethyl formamide	Stimulation Index	Result
10	1.80	Negative
25	2.52	Negative
50	4.24	Positive

The concentration of test material expected to cause a 3 fold increase in³HTdR incorporation (EC₃value) was calculated to be

32.0%. The test material was considered to be a sensitiser under the conditions of the test.